ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,715Medicare Part D Prescriptions Filled, Including Refills

Rank: 11 out of 251

$545K Total Retail Price of All Prescriptions

Rank: 12 out of 251

306 Patients Receiving at Least One Drug in Part D
70%Patients 65 Years and Older
48% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Hampshire
Lower avg

Schedule Two
Controlled Substances

15% of this provider’s 306 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

7% of this provider’s 306 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 6,013 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Hampshire
SIMVASTATIN 478 378 1 1
LEVOTHYROXINE SODIUM 372 277 2 3
AMLODIPINE BESYLATE 258 234 3 4
LISINOPRIL 205 169 4 2
OMEPRAZOLE 200 143 5 5
FUROSEMIDE 189 134 6 6
ATENOLOL 187 144 7 12
METOPROLOL TARTRATE 173 155 8 7
METFORMIN HCL 171 131 9 10
METOPROLOL SUCCINATE 168 130 10 13
SERTRALINE HCL 159 107 11 22
PANTOPRAZOLE SODIUM 140 124 12 20
ATORVASTATIN CALCIUM 107 97 13 8
OXYCODONE HCL 102 33 S2 14 30
CITALOPRAM HBR 99 54 15 15
NEXIUM 97 65 16 28
HYDROCHLOROTHIAZIDE 97 75 16 9
POTASSIUM CHLORIDE 89 65 18 33
WARFARIN SODIUM 86 71 19 11
METFORMIN HCL ER 81 48 20 65
TRIAMTERENE-HCTZ 76 76 21 53
GABAPENTIN 75 41 22 16
CELEBREX 72 29 23 81
ALLOPURINOL 71 66 24 34
HYDROCODONE-ACETAMINOPHEN 68 19 S3 25 18
LOVASTATIN 68 58 25 31
FAMOTIDINE 66 39 27 75
BUPROPION HCL SR 64 16 28 128
TORSEMIDE 64 51 28 102
PROPRANOLOL HCL 61 24 30 149
TRAZODONE HCL 59 45 31 26
ZOLPIDEM TARTRATE 58 40 32 19
CYCLOBENZAPRINE HCL 58 0 R 32 57
LOSARTAN POTASSIUM 57 49 34 17
AMITRIPTYLINE HCL 55 30 R 35 70
PREDNISONE 53 46 36 27
ACTOS 53 37 36 151
COMBIVENT 53 25 36 118
TRAMADOL HCL 52 39 39 24
KLOR-CON M20 52 48 39 45
SPIRONOLACTONE 51 30 41 54
OXYCODONE-ACETAMINOPHEN 50 13 S2 42 55
PRAVASTATIN SODIUM 50 37 42 14
GEMFIBROZIL 50 28 42 98
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 3, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.